Mednax (MD) to Release Quarterly Earnings on Thursday
Mednax (NYSE:MD) is scheduled to issue its quarterly earnings data on Thursday, July 31st. Mednax has set its Q2 guidance at $0.79-0.84 EPS.Parties that wish to listen to the company’s conference call can do so using this link.
Mednax (NYSE:MD) last issued its quarterly earnings data on Thursday, May 1st. The company reported $0.63 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.63. The company had revenue of $566.00 million for the quarter, compared to the consensus estimate of $574.80 million. During the same quarter last year, the company posted $1.10 earnings per share. Mednax’s revenue was up 12.7% compared to the same quarter last year. On average, analysts expect Mednax to post $3.16 EPS for the current fiscal year and $3.43 EPS for the next fiscal year.
Mednax (NYSE:MD) opened at 58.41 on Wednesday. Mednax has a 52-week low of $48.115 and a 52-week high of $64.51. The stock’s 50-day moving average is $58.1 and its 200-day moving average is $58.66. The company has a market cap of $5.787 billion and a P/E ratio of 20.34.
A number of research firms have recently commented on MD. Analysts at Susquehanna initiated coverage on shares of Mednax in a research note on Tuesday, July 8th. They set a “positive” rating on the stock. Analysts at Dougherty & Co raised their price target on shares of Mednax from $63.00 to $66.00 in a research note on Monday, May 5th. They now have a “buy” rating on the stock. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $83.40.
MEDNAX, Inc (NYSE:MD) is a provider of physician services, including newborn, maternal-fetal, pediatric subspecialties and anesthesia care.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.